ACAD
ACADIA Pharmaceuticals Inc
26.40$
-3.3%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -31.8% | +152.9% | -31.5% | +40.5% | +45.0% | -0.1% | -10.5% | -16.0% | +27.4% | +58.6% | +31.7% | |
| – | -32.5% | +150.2% | -31.8% | +40.9% | +44.5% | -5.6% | -13.9% | -17.8% | +21.3% | +52.3% | +13.2% | |
| – | +65.1% | +60.2% | -57.6% | +94.1% | +40.8% | +71.9% | -54.8% | -22.1% | +64.3% | +69.4% | -44.4% | |
| – | -33.3% | +145.9% | -35.5% | +38.7% | +47.3% | -9.4% | -17.6% | -20.0% | +5.3% | +72.3% | +8.4% | |
| – | +69.9% | +335.9% | +158.1% | +50.8% | +36.3% | +32.8% | +30.0% | -3.5% | +62.3% | +2.3% | +41.6% | |
| – | – | – | +25.7% | -22.4% | +55.8% | +52.7% | -18.6% | -15.8% | +439.8% | -38.7% | +58.0% | |
| – | +298.4% | +39.9% | -13.6% | +24.3% | -3.9% | +188.1% | +623.9% | -7.1% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | -21.1% | -26.7% | -36.4% | -57.1% | – | – | – | +82.9% | -9.1% | |
| – | +38.6% | +93.1% | +15.2% | +24.2% | +37.5% | +85.1% | +2.3% | +17.7% | +69.3% | +43.4% | -26.0% | |
| – | +38.3% | +94.4% | +15.1% | +21.5% | +25.6% | +41.6% | -9.3% | +30.8% | +102.4% | +55.3% | -29.8% | |
| – | – | – | – | – | – | +48.1% | +63.2% | +12.1% | +1.1% | +5.9% | +16.8% | |
| – | -17.1% | +134.0% | +124.6% | -64.0% | +128.0% | +17.6% | -19.0% | +85.4% | +37.6% | -7.7% | -32.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -35.5% | +159.5% | -35.3% | +42.9% | +45.9% | -10.3% | -13.7% | -26.0% | +7.8% | +69.7% | +67.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +3.5% | +15.1% | +5.8% | +3.2% | +16.3% | +6.9% | +2.0% | +0.7% | +1.3% | +1.6% | +3.0% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.